Therapy for Chronic Hepatitis B Infection

  • Norah A. Terrault
  • Teresa L. Wright
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

There are many parallels between hepatitis B virus (HBV) infection and that of human immunodeficiency virus (HIV). HBV is a partially double-stranded DNA virus which replicates through an RNA intermediate to produce viral DNA, a process which requires a viral reverse transcriptase. Hence reverse transcriptase inhibitors which are effective for HIV infection may also be active toward HBV. HBV is transmitted by the same mechanisms as is HIV (sexual, parenteral and perinatal exposure) and hence there are many similarities in the epidemiology of these two viruses. Like patients with HIV infection, patients with chronic HBV infection are at risk of developing complications after years or even decades of infection.

Keywords

Chronic Hepatitis Chronic Active Hepatitis Million Unit Active Viral Replication Duck Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Margolis HS, Alter MJ, Hadler SC. Hepatitis B. evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Schaffner W, P Gardner. Hepatitis B immunization strategies, expanding the target. Ann Intern Med 1993; 118: 308–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990; S18–20.Google Scholar
  4. 4.
    De Jongh FE, Janssen HL, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630–35.PubMedGoogle Scholar
  5. 5.
    Hadziyannis SJ, Lieverman HM, Karvountzis GG, et al. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg versus anti-HBe positive carriers of hepatitis B. Hepatology 1983; 3: 656–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Alberti A, Pontisso P, Fattovich G, et al. Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: Results of a long-term follow-up study of 138 patients.J Infect Dis 1986; 154: 5629.Google Scholar
  7. 7.
    Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32294–8.Google Scholar
  8. 8.
    Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B: An analysis of 379 patients. Ann Intern Med 1984; 101: 613–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Bealey RP. Hepatitis B. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–56.CrossRefGoogle Scholar
  11. 11.
    McMahon BJ, Alward WCM, Hall DB, et al. Acute hepatitis B virus infection, relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1984, 151: 599603.Google Scholar
  12. 12.
    Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type I infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138–40_Google Scholar
  13. 13.
    Hoofnagle JH_ Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy ” HBsAg carrier state_ Hepatology 1987; 7: 758–63.Google Scholar
  14. 14.
    de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191–4_Google Scholar
  15. 15.
    Lok ASF, Lai CL. Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839–43_Google Scholar
  16. 16.
    Wong DKH, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Lok ASF, Liang RHS, Chiu EKW, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100: 182–8.PubMedGoogle Scholar
  18. 18.
    Nair PV, Tong MJ, Stevenson D, et al. Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5: 8–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Scullard GH, Smith CI, Merigan TC, et al. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987–91.PubMedGoogle Scholar
  20. 20.
    Wright TL, Venook AP, Milward-Sadler, et al. Hepatic tumors. In: Wright’s liver and biliary disease. 3rd edition ed. WB Saunders Company Ltd., 1992.Google Scholar
  21. 21.
    Marion P. Development of antiviral therapy for chronic infection with hepatitis B virus. Curr Top Microbiol Immunol 1991; 168: 166–83.Google Scholar
  22. 22.
    Seeger C, Summers J, Mason W. Viral DNA synthesis. Curr Top Microbiol Immunol 1991; 168: 41–59.PubMedCrossRefGoogle Scholar
  23. 23.
    Milch D. Immune response to hepatitis B virus proteins: relevance of the mutine model. Semin Liver Dis 1991; 11: 93–112.CrossRefGoogle Scholar
  24. 24.
    Naoumov NV, Eddleston ALWF. Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus. Gut 1994; 35: 1013–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Penna A, Chisari FV, Bertoletti G, et al. Cytotoxic T lymphocytes recognise an HLA-A2 restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Civitico G, Wang YY, Luscombe C, et al. Antiviral strategies in chronic hepatitis B virus infection: Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990; 31: 90–97.PubMedCrossRefGoogle Scholar
  27. 27.
    Doong S-L, Tsai C-H, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2’3’dideoxy-3’thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495–99.PubMedCrossRefGoogle Scholar
  28. 28.
    Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95: 341–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335–40.PubMedGoogle Scholar
  30. 30.
    Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9: 235–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Hoofnagle JH, Jones EA. Interferon therapy for chronic viral hepatitis. Semin Liver Dis 1989; 9: 235–39.CrossRefGoogle Scholar
  32. 32.
    Greenberg HB, Pollard RB, Lutwick LI, et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Scullard GH, Alberti A, Wansbrough-Jones MH, et al. Effects of human leukocyte interferon on hepatitis B virus replication and immune responses in patients with chronic hepatitis B infection. J Clin Lab Immunol 1979; 1: 277–82.PubMedGoogle Scholar
  34. 34.
    Bryson Y. Effects of interferon on host resistance to virus infection. Ann Intern Med 1982; 96: 80–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Heron I, Hokland M, Berg K. Enhanced expression of beta-2 microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978; 75: 6215–19.PubMedCrossRefGoogle Scholar
  36. 36.
    Welsh RM, Hallenback LA. Effect of virus infections on target cell susceptibility to natural killer cell-mediated lysis. J Immunol 1980; 124: 2491–97.PubMedGoogle Scholar
  37. 37.
    Castilla A, Prieto J, Fausto N. Transforming growth factor bl and a in chronic liver disease. N Engl J Med 1991; 324: 933–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Perrillo RP, Schiff ER, Davis GL, et al. A randomised, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301.PubMedCrossRefGoogle Scholar
  39. 39.
    Carreno V, Castillo I, Molina J, et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatology 1992; 15: 102–6.CrossRefGoogle Scholar
  40. 40.
    Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Lok ASF, Chung HT, Liu VWS, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833–8.PubMedGoogle Scholar
  42. 42.
    Kuhns M, McNamara A, Mason A, et al. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103: 1649–56.PubMedGoogle Scholar
  43. 43.
    Lok ASK, Lai CL, Lau JYN. Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects of hepatitis B virus DNA in the liver. Gastroenterology 1991; 100: 756–61.PubMedGoogle Scholar
  44. 44.
    Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991; 115: 113–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Hoofnagle JH, DiBisceglie AM, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116–21.PubMedGoogle Scholar
  46. 46.
    Nevens F, Goubau P, Van Eyken P, et al. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon. Liver 1993; 13: 15–9.PubMedGoogle Scholar
  47. 47.
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to a-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Lok ASK, Lai CL, Wu PC, et al. Long-term follow-up of a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298–302.PubMedCrossRefGoogle Scholar
  49. 49.
    Lok ASK, Wu PC, Lau JYN, et al. Treatment of chronic hepatitis B with interferon: experience with Asian patients. Sem Liver Dis 1989; 9: 249–53.CrossRefGoogle Scholar
  50. 50.
    Lai CL, Lok ASK, Lin HJ, et al. Placebo-controlled trial of recombinant a2-interferon in Chinese HBsAgcarrier children. Lancet 1987; 2: 877–80.PubMedCrossRefGoogle Scholar
  51. 51.
    McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant a-interferon. Hepatology 1987; 7: 7 1923.Google Scholar
  52. 52.
    Lok ASF, Weller IVD, Karayiannis P, et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4: 45–9.PubMedGoogle Scholar
  53. 53.
    Bruch HR, Korn A, Klein H, et al. Treatment of chronic hepatitis B with interferon a-2b and interleukin2. J Hepatology 1993; 17: S52–5.CrossRefGoogle Scholar
  54. 54.
    DiBisceglie AM, Rustgi VK, Kassianides C, et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11: 266–70.CrossRefGoogle Scholar
  55. 55.
    Fattovich G, Giustina G, Brollo L, et al. Therapy for chronic hepatitis B with lymphoblastoid interferon-a and levamisole. Hepatology 1992; 16: 1115–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Garcia G, Smith CI, Weissberg JI, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Ann Intern Med 1987; 107: 278–85.PubMedCrossRefGoogle Scholar
  57. 57.
    Janssen FILA, Berk L, Heijtink RA, et al. Interferon-a and zidovudine combination therapy for chronic hepatitis B: Results of a randomised, placebo-controlled trial. Hepatology 1993; 17: 383–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Lau JYN, Lai CL, Wu PC, et al. A randomised controlled trial of recombinant interferon-g in Chinese patients with chronic hepatitis B virus infection. J Med Virology 1991; 34: 184–7.CrossRefGoogle Scholar
  59. 59.
    Rasi G, Mutchnick MG, DiVirgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin al therapy in the treatment of chronic hepatitis B. Hepatology 1994; 20: 299A.Google Scholar
  60. 60.
    Kakuma S, Ishikawa T, Mirokami M, et al. Treatment of human gamma interferon of chronic hepatitis B: Comparative study with alpha interferon. J Med Virol 1991; 35: 32–37.CrossRefGoogle Scholar
  61. 61.
    Marcellin P, Loriot MA, Boyer N, et al. Recombinant human interferon-y in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects. Hepatology 1990; 12: 155–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Caselmann WH, Eisenburg J, Hofschneider PH, et al. r3 and interferon-y in chronic active hepatitis B. Gastroenterology 1989; 96: 449–55.PubMedGoogle Scholar
  63. 63.
    Kagawa T, Morizane T, Saito H, et al. A pilot study of long-term weekly interferon-b administration for chronic hepatitis B. Am J Gastro 1993; 88: 212–6.Google Scholar
  64. 64.
    Drew WL, Miner R, King D. Antiviral activity of FIAU (1-(2’-deoxy-2’-fluoro-l-beta-Darabinofuranosy)-5-iodo-uridine) on strains on cytomegalovirus sensitive and resistant to ganciclovir. J Infect Dis 1991; 163: 1388–89.PubMedCrossRefGoogle Scholar
  65. 65.
    Fourel O, Hantz O, Jacquet J, et al. Effects of 2’-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol 1992; 37: 122–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Lopez C, Watanabe KA, Fox JJ. 2’-Fluoro-5-iodoaracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother 1980; 17: 803–6.Google Scholar
  67. 67.
    Fourel I, Hantz O, Watanabe A, et al. Inhibitory effects of 2’fluoro arabinosyl pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 1990: 34: 473–75.PubMedCrossRefGoogle Scholar
  68. 68.
    Fried MW, DiBisceglie AM, Straus SE, et al. FIAU, a new oral antiviral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992;16: I27A.Google Scholar
  69. 69.
    Marwick C. NIH panel report of “no flaws’ in FIAU trial at variance with FDA report, new probe planned. JAMA 1994; 272: 9–11.PubMedCrossRefGoogle Scholar
  70. 70.
    Colacino JM, Malcolm SK, Jaskunas SR. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 1994; 38: 1997 2002.Google Scholar
  71. 71.
    Klecker RW, Katki AG, Collins JM. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for I-(2’-fluoro-2’-deoxy-beta-D-arabinofuranosly)-5-iodouracil in U-937 and MOLT-4 cells. Molecular Pharmacology 1994; 46: 1204–9.PubMedGoogle Scholar
  72. 72.
    Sallie R, Kleiner D, Richardson F, et al. Mechanisms of FIAU induced hepatotoxicity. Hepatology 1994, 29: 209A.Google Scholar
  73. 73.
    Korba BE, Gerin JL Use of a standardised cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Research 1992; 17: 1–16.CrossRefGoogle Scholar
  74. 74.
    Tyrrell DLJ, Fisher K, Savani K, et al. Treatment of chimpanzees and ducks with lamivudine, 2’3’ dideoxy 3’ thiacytidine results in rapid suppression of hepadnaviral DNA in sera. Clin Invest Med 1993; 16: 487A.Google Scholar
  75. 75.
    Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor 3TC in patients with HIV infection: a phase I study. AIDS 1992; 6: 1471–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Dienstag JL, Perrillo RP, Schiff ER, et al. Double-blind, randomised, three-month, dose-ranging trial of lamivudine for chronic hepatitis B. Hepatology 1994; 20: 199A.Google Scholar
  77. 77.
    Lai CL, Ching CK, Ting A, et al. Short term lamivudine suppresses HBV DNA in Chinese HBsAg carriers. Hepatology 1994; 20: 298A.Google Scholar
  78. 78.
    Tyrrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatalogy 1993; 112A.Google Scholar
  79. 79.
    Berk L, Schalm SW, de Man R, et al. Failure of acyclovir to enhance the antiviral effect of a lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomised controlled trial. J Hepatology 1992; 305–9.Google Scholar
  80. 80.
    Chossegros P, Pouteil-Noble C, Causse X, et al. Ganciclovir is an effective antiviral agent for posttransplant chronic HBV infection but maintenance therapy is required. J Hepatol 1992; 16 (suppl): S9.Google Scholar
  81. 81.
    Gish RG, Imperial JI, Esquivel CO, et al. Ganciclovir treatment of severe hepatitis B virus (HBV) infection. Gastroenterology 1993; 104: A908.Google Scholar
  82. 82.
    Shaw T, Amor P, Civitico G, et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719–23.PubMedCrossRefGoogle Scholar
  83. 83.
    Tsiquaye KN. Famciclovir prophylaxis of acute duck hepatitis B virus (HBDV) infection in pekin ducklings. In: Proceedings of 1993 International Symposium on Viral Hepatitis and Liver Disease. 1993: A223.Google Scholar
  84. 84.
    Tillmann HL, Trautwein CH, Bode U, et al. Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir. Hepatology 1994; 20: 130A.Google Scholar
  85. 85.
    Abramowicz M. Famciclovir for herpes zoster. The Medical Letter 1994 October 28, 1994: 97–8.Google Scholar
  86. 86.
    Bassendine MF, Chadwick RG, Salmeron J, et al. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology 1981; 80: 1016–22.PubMedGoogle Scholar
  87. 87.
    Pollard RB, Smith JL, Neal EA, et al. Effect of vidarabine on chronic hepatitis B virus infection. JAMA 1978; 239: 1648–50.PubMedCrossRefGoogle Scholar
  88. 88.
    Weller IVD, Bassendine MF, Craxi A, et al. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5’monophosphate (ARA-AMP). Gut 1982; 23: 717–23.PubMedCrossRefGoogle Scholar
  89. 89.
    Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1994; 38: 616–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Schinazi RF, Gosselin G, Faraj A, et al. Pure nucleoside enantiomers of beta-2’3’-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother 1994; 38: 2172–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Hess G, Rossol S, Voth R, et al. Treatment of patients with chronic type B hepatitis and concurrent infection with the immunodeficiency virus with a combination of interferon alpha and azidothymidine: a pilot study. Digestion 1989; 43: 56–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34: S106.PubMedCrossRefGoogle Scholar
  93. 93.
    Catterall AP, Moyle GJ, Hopes EA, et al. Dideoxyinosine for chronic hepatitis B infection. J Med Virol 1992; 37: 307–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Low UK, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus 1984; 6: 27–42.PubMedGoogle Scholar
  95. 95.
    Wetzel R, Heyneker HL, Goeddel DV, et al. Production of biologically active Na-desacetlythymosin al in E. Coli through expression of a chemically synthesised gene. Biochem 1980; 19: 6096–6104.Google Scholar
  96. 96.
    Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. J Biol Chem 1979; 254: 981–6.PubMedGoogle Scholar
  97. 97.
    Korba BE, Tennant BC, Cote PJ, et al. Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1. Hepatology 1990; 12: A880.Google Scholar
  98. 98.
    Mutchnick MG, Schaffner JA, Prieto JA, et al. Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci 1983; 28: 328–33.PubMedCrossRefGoogle Scholar
  99. 99.
    Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot study. Hepatology 1991; 14: 409–15.PubMedCrossRefGoogle Scholar
  100. 100.
    Mutchnick MG, Jaurequi JI, Shafritz DA. Sustained response to thymosin therapy in patients with chronic hepatitis B. Hepatology 1992; 16: 66A.Google Scholar
  101. 101.
    Mutchnick MG, Jaurequi JI, Shafritz DA. Randomised, controlled trial of thymosin in the treatment of chronic hepatitis B. Gastroenterology 1995; 108: A1127.Google Scholar
  102. 102.
    Renoux G. The general immunopharmacology of levamisole. Drugs 1980; 20: 89–99.PubMedCrossRefGoogle Scholar
  103. 103.
    Peters M, Vierling J, Gershwin ME, et al. Immunology and the liver. Hepatology 1991; 13: 977–94.PubMedCrossRefGoogle Scholar
  104. 104.
    Fattovich G. Brollo L, Pontisso P, et al. Levamisole therapy in chronic type B hepatitis. Results of a double-blind randomised trial. Gastroenterology 1986; 91: 692–6.PubMedGoogle Scholar
  105. 105.
    Borsh O, Moraleda G, Castillo I, et al. Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J Hepatol 1993; 19: 437–41.CrossRefGoogle Scholar
  106. 106.
    Ruiz-Moreno M, Garcia R, Rua W, et al. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993; 18: 264–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Henry CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cytotoxicity. Nature 1981; 291: 335–7.CrossRefGoogle Scholar
  108. 108.
    Nakagawa H, Hirano T, Nakagawa N, et al. Effect of recombinant IL-2 and g-IFN on proliferation and differentiation of human B cells. J Immunol 1985; 134: 959–66.PubMedGoogle Scholar
  109. 109.
    Rosenberg SA, Grimm EA, McGorgan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Guidotti LG, Guilhot S, Chisari FV. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways. J Virol 1994; 68: 1265–70.PubMedGoogle Scholar
  111. 111.
    Naruo K, Hinuma S, Kato K, et al. Comparison of the biological properties of purified natural and recombinant interleukin-2. Bioch Biophys Res Commun 1985; 128: 257–64.CrossRefGoogle Scholar
  112. 112.
    Kakumu S, Fuji A, Yoshioka K, et al. Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 1988; 8: 487–92.PubMedCrossRefGoogle Scholar
  113. 113.
    Nishioka M, Kagawa H, Shirai M, et al. Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: A preliminary report. Am J Gastro 1987; 82: 438–42.Google Scholar
  114. 114.
    Onji M, Kondoh H, Horike N, et al. Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. Gut 1987; 28: 1648–52.PubMedCrossRefGoogle Scholar
  115. 115.
    Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class I-restricted human cytotoxic T cells recognize synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Lam KC, Lai Cl, Trepo C, et al. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1980; 304: 380–4.CrossRefGoogle Scholar
  117. 117.
    Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B infection. Gastroenterology 1980; 79. 195–9.PubMedGoogle Scholar
  118. 118.
    Nair PV, Tong MJ, Stevenson D, et al. Effect of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5: 8–12.PubMedCrossRefGoogle Scholar
  119. 119.
    Fevery J, Elewaut A, Michielson P, et al. Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study. JHepatology 1990; 11: 5108–112.Google Scholar
  120. 120.
    Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992: 102: 2091–7.PubMedGoogle Scholar
  121. 121.
    Flowers M, Sherker A, Sinclair SB. et al. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation_ Transplantation 1994; 58: 183–92.Google Scholar
  122. 122.
    Kakumu S, Yoshioka K, Wakita T, et al. Pilot study of ribavirin and interferon-b for chronic hepatitis B. Hepatology 1993; 18: 258–63.PubMedCrossRefGoogle Scholar
  123. 123.
    Martin J, Bosch P, Quiroga JA, et al. Recombinant human granuloctye-macrophage colony-stimulating factor (rhGM-CSF) in the treatment of chronic hepatitis B. Hepatology 1992, 16: 67A.Google Scholar
  124. 124.
    Thyagarajan SP, Subramanian S, Thirunalasundari T, et al. Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 1988;ii:764–6.Google Scholar
  125. 125.
    Tong MJ, Hwang SJ, Lefkowitz M. et al. A pilot, open labeled, phase II study using ribavirin in the treatment of patients with chronic active hepatitis B. Clinical and Diagnostic Virology 1995;in press.Google Scholar
  126. 126.
    Freiman JS, Murray SM, Vickery K, et al. Postexposure treatment of experimental DHBV infection: a new therapeutic strategy. J Med Virol 1990; 30272–6.Google Scholar
  127. 127.
    Bain VGF, Daniels JIM, Chanas A et al. Foscarnet therapy in chronic hepatitis B virus E antigen carriers. J Med Virol 1989; 29: 152–5.CrossRefGoogle Scholar
  128. 128.
    Schvarz R, Hansson BG, Larnestedt JO et al. Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet. Infection 1994; 22: 330–2.CrossRefGoogle Scholar
  129. 129.
    Angus P, Richards M, Bowden S et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroent and Hepatol 1993; 8: 353–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Norah A. Terrault
  • Teresa L. Wright

There are no affiliations available

Personalised recommendations